沟通钠-葡萄糖协同转运蛋白2抑制剂的新出现风险——药品监管机构的及时性与透明度 - Suppr

Communicating emerging risks of SGLT2 inhibitors-timeliness and transparency of medicine regulators.

作者信息

Bhasale Alice, Mintzes Barbara, Sarpatwari Ameet

机构信息

University of Sydney Charles Perkins Centre and School of Pharmacy, Faculty of Medicine and Health, 6W75, The Hub, Charles Perkins Centre D17, University of Sydney, NSW 2006, Australia

University of Sydney Charles Perkins Centre and School of Pharmacy, Faculty of Medicine and Health, 6W75, The Hub, Charles Perkins Centre D17, University of Sydney, NSW 2006, Australia.

出版信息

BMJ. 2020 Apr 29;369:m1107. doi: 10.1136/bmj.m1107.

DOI:10.1136/bmj.m1107

PMID:32349976

Abstract

摘要

相似文献

Communicating emerging risks of SGLT2 inhibitors-timeliness and transparency of medicine regulators.

BMJ. 2020 Apr 29;369:m1107. doi: 10.1136/bmj.m1107.

Safety of Sodium-Glucose Co-Transporter 2 Inhibitors.

Am J Cardiol. 2019 Dec 15;124 Suppl 1:S45-S52. doi: 10.1016/j.amjcard.2019.10.029.

SGLT2 inhibitors for diabetes are linked to increased risk of lower limb amputation.

BMJ. 2018 Nov 14;363:k4828. doi: 10.1136/bmj.k4828.

Potential Safety Issues with Use of Sodium-Glucose Cotransporter 2 Inhibitors, Particularly in People with Type 2 Diabetes and Chronic Kidney Disease.

Drug Saf. 2020 Dec;43(12):1211-1221. doi: 10.1007/s40264-020-01010-6. Epub 2020 Oct 23.

Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis.

BMJ Open. 2019 Feb 1;9(1):e022577. doi: 10.1136/bmjopen-2018-022577.

Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with CKD and Type 2 Diabetes: Population-Based US Cohort Study.

Clin J Am Soc Nephrol. 2023 May 1;18(5):592-601. doi: 10.2215/CJN.0000000000000115. Epub 2023 Feb 24.

Clinical Adverse Events Associated with Sodium-Glucose Cotransporter 2 Inhibitors: A Meta-Analysis Involving 10 Randomized Clinical Trials and 71 553 Individuals.

J Clin Endocrinol Metab. 2021 Jun 16;106(7):2133-2145. doi: 10.1210/clinem/dgab274.

Safety of four SGLT2 inhibitors in three chronic diseases: A meta-analysis of large randomized trials of SGLT2 inhibitors.

Diab Vasc Dis Res. 2021 Mar-Apr;18(2):14791641211011016. doi: 10.1177/14791641211011016.

Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials.

Diabetes Obes Metab. 2018 Mar;20(3):620-628. doi: 10.1111/dom.13124. Epub 2017 Oct 26.

Sodium-Glucose Cotransporter 2 Inhibitors: A Case Study in Translational Research.

Diabetes. 2019 Jun;68(6):1109-1120. doi: 10.2337/dbi18-0006.

引用本文的文献

Safety Warnings on the Same Harmful Effects of Medicines: A Comparison of Four National Regulators.

Pharmaceut Med. 2025 Jun 25. doi: 10.1007/s40290-025-00573-y.

Comparison of safety profiles for dapagliflozin based on EMA and FDA safety issues: Challenges and future of post-marketing surveillance in Korea.

PLoS One. 2024 Nov 22;19(11):e0314363. doi: 10.1371/journal.pone.0314363. eCollection 2024.

What Factors Make EU Regulators Want to Communicate Drug Safety Issues Related to SGLT2 Inhibitors? An Online Survey Study.

Drug Saf. 2023 Mar;46(3):243-255. doi: 10.1007/s40264-022-01270-4. Epub 2023 Feb 15.

Are Corporations Re-Defining Illness and Health? The Diabetes Epidemic, Goal Numbers, and Blockbuster Drugs.

J Bioeth Inq. 2021 Sep;18(3):477-497. doi: 10.1007/s11673-021-10119-x. Epub 2021 Sep 6.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Communicating emerging risks of SGLT2 inhibitors-timeliness and transparency of medicine regulators.

作者信息

Bhasale Alice, Mintzes Barbara, Sarpatwari Ameet

机构信息

University of Sydney Charles Perkins Centre and School of Pharmacy, Faculty of Medicine and Health, 6W75, The Hub, Charles Perkins Centre D17, University of Sydney, NSW 2006, Australia

University of Sydney Charles Perkins Centre and School of Pharmacy, Faculty of Medicine and Health, 6W75, The Hub, Charles Perkins Centre D17, University of Sydney, NSW 2006, Australia.

出版信息

BMJ. 2020 Apr 29;369:m1107. doi: 10.1136/bmj.m1107.

DOI:10.1136/bmj.m1107

PMID:32349976

Abstract

摘要

相似文献

Communicating emerging risks of SGLT2 inhibitors-timeliness and transparency of medicine regulators.

BMJ. 2020 Apr 29;369:m1107. doi: 10.1136/bmj.m1107.

Safety of Sodium-Glucose Co-Transporter 2 Inhibitors.

Am J Cardiol. 2019 Dec 15;124 Suppl 1:S45-S52. doi: 10.1016/j.amjcard.2019.10.029.

SGLT2 inhibitors for diabetes are linked to increased risk of lower limb amputation.

BMJ. 2018 Nov 14;363:k4828. doi: 10.1136/bmj.k4828.

Potential Safety Issues with Use of Sodium-Glucose Cotransporter 2 Inhibitors, Particularly in People with Type 2 Diabetes and Chronic Kidney Disease.

Drug Saf. 2020 Dec;43(12):1211-1221. doi: 10.1007/s40264-020-01010-6. Epub 2020 Oct 23.

Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis.

BMJ Open. 2019 Feb 1;9(1):e022577. doi: 10.1136/bmjopen-2018-022577.

Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with CKD and Type 2 Diabetes: Population-Based US Cohort Study.

Clin J Am Soc Nephrol. 2023 May 1;18(5):592-601. doi: 10.2215/CJN.0000000000000115. Epub 2023 Feb 24.

Clinical Adverse Events Associated with Sodium-Glucose Cotransporter 2 Inhibitors: A Meta-Analysis Involving 10 Randomized Clinical Trials and 71 553 Individuals.

J Clin Endocrinol Metab. 2021 Jun 16;106(7):2133-2145. doi: 10.1210/clinem/dgab274.

Safety of four SGLT2 inhibitors in three chronic diseases: A meta-analysis of large randomized trials of SGLT2 inhibitors.

Diab Vasc Dis Res. 2021 Mar-Apr;18(2):14791641211011016. doi: 10.1177/14791641211011016.

Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials.

Diabetes Obes Metab. 2018 Mar;20(3):620-628. doi: 10.1111/dom.13124. Epub 2017 Oct 26.

Sodium-Glucose Cotransporter 2 Inhibitors: A Case Study in Translational Research.

Diabetes. 2019 Jun;68(6):1109-1120. doi: 10.2337/dbi18-0006.

引用本文的文献

Safety Warnings on the Same Harmful Effects of Medicines: A Comparison of Four National Regulators.

Pharmaceut Med. 2025 Jun 25. doi: 10.1007/s40290-025-00573-y.

Comparison of safety profiles for dapagliflozin based on EMA and FDA safety issues: Challenges and future of post-marketing surveillance in Korea.

PLoS One. 2024 Nov 22;19(11):e0314363. doi: 10.1371/journal.pone.0314363. eCollection 2024.

What Factors Make EU Regulators Want to Communicate Drug Safety Issues Related to SGLT2 Inhibitors? An Online Survey Study.

Drug Saf. 2023 Mar;46(3):243-255. doi: 10.1007/s40264-022-01270-4. Epub 2023 Feb 15.

Are Corporations Re-Defining Illness and Health? The Diabetes Epidemic, Goal Numbers, and Blockbuster Drugs.

J Bioeth Inq. 2021 Sep;18(3):477-497. doi: 10.1007/s11673-021-10119-x. Epub 2021 Sep 6.

Communicating emerging risks of SGLT2 inhibitors-timeliness and transparency of medicine regulators.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Communicating emerging risks of SGLT2 inhibitors-timeliness and transparency of medicine regulators.

作者信息

机构信息

出版信息

相似文献

引用本文的文献